CYP19A1 and breast cancer: Although the sample size of higher-risk subgroup was as small as 17 patients, the result is consistent with recent guidelines, which recommend combination with 5-year OFS and tamoxifen or aromatase inhibitor (AI) for higher-risk premenopausal patients as an endocrine adjuvant therapy for resected early stage breast cancer [18].